Evidence Archives

Performance Characteristics of the MammaPrint® Breast Cancer Diagnostic Gene Signature
Gallery
Performance Characteristics of the MammaPrint® Breast Cancer Diagnostic Gene Signature

Evidence, MammaPrint, Other, Validation

Performance Characteristics of the MammaPrint® Breast Cancer Diagnostic Gene Signature

PUBLICATION: PERSONALIZED MEDICINE VOL. 10, NO. 8 | 17 Oct Read More

kevin2024-03-25T10:42:18-07:00October 17th, 2013|Evidence, MammaPrint, Other, Validation|

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

Adjuvant, BluePrint, Evidence

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Read More

kevin2024-03-25T10:44:00-07:00August 4th, 2013|Adjuvant, BluePrint, Evidence|

Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience
Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience

Adjuvant, Evidence, MammaPrint

Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience

PUBLICATION: Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. Read More

kevin2024-03-07T12:14:52-08:00August 1st, 2013|Adjuvant, Evidence, MammaPrint|

MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer
MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer

Adjuvant, Evidence, MammaPrint

MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer

PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. Read More

kevin2024-03-25T10:45:11-07:00July 3rd, 2013|Adjuvant, Evidence, MammaPrint|

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

Adjuvant, Evidence, MammaPrint, MINDACT, Other

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl Read More

kevin2024-03-25T10:45:47-07:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More

kevin2024-03-25T10:46:58-07:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
Gallery
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

Evidence, Healthcare Economics, MammaPrint, Other

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

kevin2024-03-25T10:47:25-07:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|

A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study
A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study

Adjuvant, Evidence, MammaPrint, RASTER

A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study

PUBLICATION: Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub Read More

kevin2024-03-25T10:47:48-07:00January 13th, 2013|Adjuvant, Evidence, MammaPrint, RASTER|

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience

Evidence, MammaPrint, Other

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience

PUBLICATION: Scientifica (Cairo). 2012; 2012: 942507. Published online 2012 Dec Read More

kevin2024-03-25T10:48:40-07:00December 31st, 2012|Evidence, MammaPrint, Other|

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer
Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

Endocrine, Evidence, MammaPrint

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

PUBLICATION: The Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun Read More

kevin2024-03-25T10:49:46-07:00December 1st, 2012|Endocrine, Evidence, MammaPrint|